Novogene Co

Novogene Co Short-term Debt

The Short-Term Debt of Novogene Co (688315.SS) as of Oct 23, 2026 is 28.97 M CNY. In the previous year, Short-Term Debt was 1.00 M CNY — a change of 2,796.85% (higher).

Short-term Debt

28.97 MCNY

YoY

2,796.85%

Last updated:

Short-Term Debt of Novogene Co is 2024 28.97 M CNY. Short-Term Debt of Novogene Co was 2023 1.00 M CNY. It decreases by 2,796.85% higher compared to the previous year.

The Novogene Co Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2016
94.93 M CNY
Jan 1, 2017
52.10 M CNY
Jan 1, 2019
182.42 M CNY
Jan 1, 2020
71.26 M CNY
Jan 1, 2021
15.57 M CNY
Jan 1, 2022
21.13 M CNY
Jan 1, 2023
1.00 M CNY
Jan 1, 2024
28.97 M CNY
The Novogene Co Short-term Debt history
YEARShort-term DebtYoY
28.97 MCNY+2,796.85%
1.00 MCNY-95.27%
21.13 MCNY+35.71%
15.57 MCNY-78.15%
71.26 MCNY-60.94%
182.42 MCNY+250.11%
52.10 MCNY-45.11%
94.93 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novogene Co Stock analysis

What does Novogene Co do? Novogene Co., Ltd. generates revenue through genomic services and solutions, primarily utilizing high-throughput sequencing and bioinformatics analysis technologies. The company offers life science basic research services, medical research and technical services, and database-building sequencing platform services, targeting both domestic and international markets. Key products include gene mutation detection kits, coronavirus disease nucleic acid test services, and DA8600 sequencers, which are sold to research institutions, medical facilities, and clinical applications. The firm's technology-driven approach enables it to provide multi-level scientific and research technical services across life science and medical fields. Novogene's revenue streams are anchored in its sequencing platforms and equipment, with the DA8600 sequencers representing a significant product line. The company develops and sells genetic testing medical equipment, leveraging its expertise in gene sequencing. Its services are tailored for life science basic research, medical and clinical applications, and database construction, serving a diverse clientele including research organizations and healthcare providers. The firm's focus on multi-omics research technology enhances its ability to deliver comprehensive solutions. The business model integrates high-throughput sequencing technology with bioinformatics analysis to create scalable services. Novogene's offerings span from basic research support to clinical diagnostic tools, with gene mutation detection kits and coronavirus disease nucleic acid test services catering to specific market needs. The company's domestic and overseas market presence ensures broad client reach, while its independent development of sequencing equipment like the DA8600 sequencers drives product-based revenue. This dual focus on services and equipment positions Novogene as a key player in genomic technology solutions. Novogene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novogene Co stock

Short-Term Debt of Novogene Co is 28.97 M CNY in 2024.

Short-Term Debt of Novogene Co changed from 1.00 M CNY to 28.97 M CNY, representing a 2,796.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Novogene Co since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Novogene Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Novogene Co

All Key Metrics — Novogene Co